Glioblastoma (GBM) is resistant to multimodality therapeutic approaches. A high burden of
tumor-specific mutant peptides (neoantigens) correlates with better survival and response to …

Glioblastoma (GBM) remains a significant cause of cancer-related mortality in pediatric and
adult patients with limited treatment options. Immunotherapy represents a promising new …

Immunotherapy applications to glioblastoma represent a new treatment frontier. Antigen-
targeted immunotherapy approaches hold enormous potential to elicit antigen-specific anti …

Neoantigens represent promising targets for personalized cancer vaccine strategies.
However, the feasibility of this approach in lower mutational burden tumors like glioblastoma …

Immune-based therapies have shown limited efficacy in glioma thus far. This might be at
least in part due to insufficient numbers of neoantigens, thought to be targets of immune …

Purpose: Outcomes for patients with glioblastoma (GBM) remain poor despite multimodality
treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options …

The ability of glioblastoma (GBM) to successfully evade and escape immunity has thwarted
many of the immunotherapeutic efforts taken up against it thus far. Despite intracranial …

Background Although clinical trials testing immunotherapies in glioblastoma (GBM) have
yielded mixed results, new strategies targeting tumor-specific somatic coding mutations …

Glioma is the most common primary brain tumor, characterized by a consistently high patient
mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial …

Despite some success in secondary brain metastases, targeted or immune-based therapies
have shown limited efficacy against primary brain malignancies such as glioblastoma …